TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00732810
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1250 mg/m\^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.
Study: NCT00603746
Drug: GW685698X
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW685698X
Study: NCT01299922
Drug: Mycophenolic Acid + prednison
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolic Acid + prednison for 106 weeks
Study: NCT01395329
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: gelatin capsule to be taken by mouth once per day for 12 weeks
Study: NCT00256919
Drug: GW856553
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04702490
Drug: MET409 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET409 Placebo (50mg)
Study: NCT01393405
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction period (week 1-16) (Open label):~25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily~Maintenance period (week 17-48) (Randomization):~25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine or Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
Study: NCT04210752
Drug: Treatment 1 (EG-HZ-001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive two single IM vaccinations, 2 months apart, the first on Day 1 and the second on Day 60 (±5 days). Subjects will be randomised to treatment at a ratio of 1:1:1:1:1 (n=8 per treatment)~Route of Administration: IM injection
Study: NCT04210752
Drug: Treatment 5
Normalized name: GNP Cold Sore Treatment 5% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shingrix~Suspension for injection supplied as a single dose vial of lyophilised VZVgE antigen component to be reconstituted with the accompanying vial of AS01B adjuvant suspension component. After reconstitution, a single dose of ShingrixTM is 0.5 mL.~Route of Administration: IM injection
Study: NCT01988116
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01524627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
Study: NCT00500370
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subcutaneous injection (equivalent volume to active dose), twice a day
Study: NCT01806896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: - Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~Dosing for 28 days.
Study: NCT01806896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.~* Dosing for 28 days.
Study: NCT04623333
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 1200mg administered intravenously (IV) on Day 1 of each 21-day cycle.
Study: NCT02444091
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.
Study: NCT00136084
Drug: Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
Study: NCT00136084
Drug: Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
Study: NCT02531412
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a major surgery event a time 0, 24h and 48h
Study: NCT02531412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a major surgery event a time 0, 24h and 48h
Study: NCT04411433
Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).~Favipiravir Favipiravir Dosage and method of administration: in a regimen of 2x1600 mg (oral) loading dose on day-1 followed by 1200 mg maintenance dose (2x600 mg, 2 times daily) on day-2 to day-5 (5 days in total). The treatment duration may be extended up to 14 days with the evaluation of principle investigator.
Study: NCT04411433
Drug: Hydroxychloroquine combined with Azithromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Hydroxychloroquine combined with Azithromycin Hydroxychloroquine Dosage and method of administration for patients with mild possible or confirmed COVID-19 pneumonia (no severe pneumonia symptoms): in a regimen of 2x400 mg (oral) loading dose on day-1 followed by 400 mg maintenance dose (2x200 mg oral, 2 times daily) on day-2 to day-5 (5 days in total).~Hydroxychloroquine Dosage and method of administration for patients with uncomplicated possible or confirmed COVID-19: in a regimen of 400 mg (2x200 mg oral, 2 times daily) throughout 5 days (5 days in total).~Azithromycin Dosage and method of administration: in a regimen of 1x500 mg (oral) loading dose on day-1 followed by 250 mg maintenance dose (oral daily) on day-2 to day-5 (5 days in total).
Study: NCT01354132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets are placed in water or juice in the AM and PM
Study: NCT00843713
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
Study: NCT01665274
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
Study: NCT00997503
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo to match both 10mg and 5mg prasugrel tablets.
Study: NCT00956930
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75mg fixed dose
Study: NCT01068444
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 30 mg/d for 6 months
Study: NCT00929955
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
Study: NCT00929955
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to TAU
Study: NCT00838266
Drug: mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
Study: NCT00721695
Drug: OMS302
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMS302 Irrigation Solution
Study: NCT00721695
Drug: OMS302-PE
Approvals — FDA: no, EMA: no, PMDA: no
Description: OMS302-PE HCI Irrigation Solution
Study: NCT00721695
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
Study: NCT01039896
Drug: Period I : SLM0807, Period II : HKB0701 and SLM0807
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01039896
Drug: Period I : HKB0710 and SLM0807, Period II : SLM0807
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03132116
Drug: gentamicin
Normalized name: Gentamicin
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).
Study: NCT03132116
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).
Study: NCT03323047
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acetaminophen (15 mg/kg) 1 hr pre-operatively
Study: NCT00452725
Drug: MAXOMAT ®, biosynthetic growth hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration
Study: NCT03102918
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive placebo over a 6-week treatment period.
Study: NCT01762943
Drug: Micronized estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.
Study: NCT01456325
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
Study: NCT01819805
Drug: No intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
Study: NCT00302003
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00302003
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00159588
Drug: Betablockers or other preventive drugs based on primary headache type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Several preventive drugs based on each individual regarding type of original headache type (i.e angiotensin II blockers, betablockers, valproate, tricyclic antidepressants or gabapentin)
Study: NCT02633956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once a day (QD) by mouth (PO)
Study: NCT02227485
Drug: Punica granatum Pleniflora (Golnaar) mouth rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patient in intervention group use 10 ml of Golnaar mouth rinse for 2 minutes every night for 2 weeks.
Study: NCT01529424
Drug: ISIS apoC-III Rx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1
Study: NCT01529424
Drug: ISIS apoC-III Rx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2
Study: NCT01529424
Drug: ISIS apoC-III Rx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 3
Study: NCT01529424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1
Study: NCT01529424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2
Study: NCT01529424
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 3
Study: NCT00882531
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03516669
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twenty patients receive intraluminal clarithromycin eradication of H. pylor.
Study: NCT03516669
Drug: Amoxicillin, Clarithromycin
Normalized name: Lansoprazole, Amoxicillin, Clarithromycin KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic rescue therapies with triple therapy which contains a proton pump inhibitor, amoxicillin and clarithromycin for 14 days.
Study: NCT00950534
Drug: Oral Anti Diabetics (OAD)
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
Study: NCT04322396
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin
Study: NCT04322396
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Azithromycin
Study: NCT04322396
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Hydroxychloroquine
Study: NCT00802412
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
Study: NCT03224702
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive placebo matched to M6495 on Day 1
Study: NCT03323047
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo 1 hr pre-operatively
Study: NCT00881946
Drug: GSK21110183
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
Study: NCT04448899
Drug: Blacebo plus standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blacebo plus standard treatment
Study: NCT02659020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT02202447
Drug: EC1169
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART A: EC1169 - Dose dependent on cohort, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 1 - taxane naive - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.~PART B: EC1169 cohort 2 - taxane exposed - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.
Study: NCT02254707
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02151448
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.
Study: NCT01163994
Drug: doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally, 100 mg, bid, 15 days
Study: NCT00621218
Drug: tretinoin gel 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea
Study: NCT00621218
Drug: vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.
Study: NCT03493490
Drug: Neodolpasse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive two infusions containing 75 mg diclofenac and 30 mg orphenadrine citrate 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
Study: NCT03493490
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive two infusions containing 75 mg diclofenac 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
Study: NCT03493490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive two physiologic saline infusions 30 minutes after fixation of the graft replacement and with a time interval of 8 hours.
Study: NCT02941679
Drug: HCP1202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hanmi Pharmaceutical. Co., Ltd.
Study: NCT02941679
Drug: HGP1011
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boehringer Ingelheim
Study: NCT02941679
Drug: HCP0910
Approvals — FDA: no, EMA: no, PMDA: no
Description: GlaxoSmithKline
Study: NCT02261376
Drug: DS-1971a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .
Study: NCT03075670
Drug: ALPROLIX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 50 IU/kg for intravenous (i.v.) injection
Study: NCT02325011
Drug: Sativex® (Treatment A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
Study: NCT02519712
Drug: Induction Chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme). Patients who achieve CR may undergo consolidation chemotherapy at the discretion of the treating leukemia physician.
Study: NCT00656630
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo capsule, 1 week duration
Study: NCT01411163
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to 30 grams daily creatine monohydrate
Study: NCT05492669
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the placebo group, the same volume of normal saline will be administered during anesthesia. The postoperative PCIA device will contain sufentanil 2 μg/kg, granisetron 12 mg diluted to 200 mL in 0.9% normal saline solution with a total volume of 200 ml.
Study: NCT02273219
Drug: AEB071
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)
Study: NCT02273219
Drug: BYL719
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds
Study: NCT04275596
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of topical placebo on the anal wound until complete wound healing
Study: NCT02321462
Drug: Fortrans®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
Study: NCT02196324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03571919
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bolus of saline and then infusion
Study: NCT02635191
Drug: Tailored Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.
Study: NCT02635191
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
Study: NCT03367377
Drug: LY3209590
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT02724904
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Bolus
Study: NCT02265822
Drug: melatonin in children premedication
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01183169
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALV placebo soft gel capsules administered orally
Study: NCT00089570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00692770
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 2 tablets twice daily (BID)
Study: NCT04321161
Drug: Bicanorm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.~sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)
Study: NCT00397800
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00917891
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: dosage form: vaginal gel~frequency: once daily~duration: 6 weeks
Study: NCT01889680
Drug: LV
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/m2 IV day 1 every 14 days until disease progression
Study: NCT01889680
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days
Study: NCT01930292
Drug: Part A: Debio 1143
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.
Study: NCT01930292
Drug: Part B: Debio 1143
Approvals — FDA: no, EMA: no, PMDA: no
Description: RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.